Biotech & Pharma

StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine Companies

32 sec read27 views0 listens

Moderna's mRNA-1010 flu vaccine application received a positive turnaround from the FDA after an initial rejection, now set for review and potentially including a post-marketing study. The company disputes the FDA's earlier stance on comparator vaccines in trials. Shares of Moderna rose while other vaccine developers saw mixed results based on their own news. Compass Pathways saw significant gains following positive trial results for its psilocybin treatment for depression, while Moleculin Biotech shares dropped after warrant exercises and stock dilution concerns.

Read the full article at Genetic Engineering News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Tech & Gadgets10 hours ago27 sec read

Canada poaches 64 global scholars in bid to bolster domestic talent pipeline

Canada has secured the relocation of 64 international academics, primarily from the U.S., to its universities under a new $1.7 billion initiative aimed at boosting research and innovation in key fields like AI, health, and environmental science. This...

Ali Nemati

Real Estate & Home1 day ago27 sec read

Unstable rental housing creating lifelong disadvantages for children, new study warns

A new study by the Australian Housing and Urban Research Institute reveals that children in rental homes move frequently and are more likely to face poor living conditions, negatively impacting their development. This instability affects physical and...

Ali Nemati

Cybersecurity1 day ago27 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati